| Gatifloxacin | hsa00340 | Histidine metabolism | 4.52E-02 | 1 | O95954 | FTCD | More | |
| Gatifloxacin | hsa00564 | Glycerophospholipid metabolism | 9.70E-03 | 2 | Q9Y259, P49619 | CHKB, DGKG | More | |
| Gatifloxacin | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Gatifloxacin | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Gatifloxacin | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Gatifloxacin | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Gatifloxacin | hsa00983 | Drug metabolism - other enzymes | 3.50E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | |
| Gatifloxacin | hsa01100 | Metabolic pathways | 2.25E-02 | 7 | Q9Y259, Q13956, P49619, O95954, Q02318, Q9UBX8, P35573 | CHKB, PDE6H, DGKG, FTCD, CYP27A1, B4GALT6, AGL | More | |
| Gatifloxacin | hsa01523 | Antifolate resistance | 2.04E-02 | 2 | P04818, P18054 | TYMS, ALOX12 | More | |
| Gatifloxacin | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | |
| Gatifloxacin | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | |
| Gatifloxacin | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | |
| Gatifloxacin | hsa03320 | PPAR signaling pathway | 1.84E-03 | 3 | O00767, Q13133, Q02318 | SCD, NR1H3, CYP27A1 | More | |
| Gatifloxacin | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 3.02E-02 | 3 | P09341, P02775, Q13651 | CXCL1, PPBP, IL10RA | More | |
| Gatifloxacin | hsa04064 | NF-kappa B signaling pathway | 1.60E-02 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | |
| Gatifloxacin | hsa04071 | Sphingolipid signaling pathway | 2.96E-02 | 5 | P21453, Q9H228, Q13362, Q9BX95, P10415 | S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | |
| Gatifloxacin | hsa04080 | Neuroactive ligand-receptor interaction | 3.22E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, Q16581 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1 | More | |
| Gatifloxacin | hsa04110 | Cell cycle | 3.57E-02 | 3 | Q9UBD5, P06493, P33981 | ORC3, CDK1, TTK | More | |
| Gatifloxacin | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | |
| Gatifloxacin | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | |
| Gatifloxacin | hsa04144 | Endocytosis | 4.10E-02 | 3 | O75351, P62491, Q14161 | VPS4B, RAB11A, GIT2 | More | |
| Gatifloxacin | hsa04210 | Apoptosis | 3.77E-02 | 8 | Q13315, P10415, O76075, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | |
| Gatifloxacin | hsa04217 | Necroptosis | 4.42E-04 | 6 | P07900, P15104, P05141, P01584, P0C0S5, Q13557 | HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, CAMK2D | More | |
| Gatifloxacin | hsa04530 | Tight junction | 2.45E-03 | 6 | Q8TEU7, P16989, P56750, O00501, Q14247, P24844 | RAPGEF6, CSDA, CLDN17, CLDN5, CTTN, MYL9 | More | |
| Gatifloxacin | hsa04612 | Antigen processing and presentation | 3.21E-02 | 6 | P13765, P48382, P26715, P26717, Q13241, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A | More | |
| Gatifloxacin | hsa04613 | Neutrophil extracellular trap formation | 1.73E-02 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Gatifloxacin | hsa04657 | IL-17 signaling pathway | 4.87E-02 | 2 | P07900, P01584 | HSP90AA1, IL1B | More | |
| Gatifloxacin | hsa04725 | Cholinergic synapse | 4.83E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | |
| Gatifloxacin | hsa04915 | Estrogen signaling pathway | 2.96E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | |
| Gatifloxacin | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | |
| Gatifloxacin | hsa04927 | Cortisol synthesis and secretion | 8.60E-03 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | |
| Gatifloxacin | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.13E-02 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | |
| Gatifloxacin | hsa04932 | Non-alcoholic fatty liver disease | 9.70E-03 | 4 | P18848, P01584, P13073, O15239 | ATF4, IL1B, COX4I1, NDUFA1 | More | |
| Gatifloxacin | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | |
| Gatifloxacin | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | |
| Gatifloxacin | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | |
| Gatifloxacin | hsa05020 | Prion disease | 3.37E-03 | 7 | P13591, P01584, P11142, O15239, P13073, P18848, P05141 | NCAM1, IL1B, HSPA8, NDUFA1, COX4I1, ATF4, SLC25A5 | More | |
| Gatifloxacin | hsa05022 | Pathways of neurodegeneration - multiple diseases | 3.80E-02 | 6 | O15239, P13073, P18848, P05141, P01584, Q13557 | NDUFA1, COX4I1, ATF4, SLC25A5, IL1B, CAMK2D | More | |
| Gatifloxacin | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Gatifloxacin | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | |
| Gatifloxacin | hsa05160 | Hepatitis C | 4.55E-02 | 3 | O00501, P29728, P01106 | CLDN5, OAS2, MYC | More | |
| Gatifloxacin | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | |
| Gatifloxacin | hsa05171 | Coronavirus disease - COVID-19 | 9.72E-03 | 7 | P01584, P62753, P25398, P36578, P32969, P18077, P62829 | IL1B, RPS6, RPS12, RPL4, RPL9, RPL35A, RPL23 | More | |
| Gatifloxacin | hsa05202 | Transcriptional misregulation in cancer | 1.77E-02 | 11 | Q15532, Q13315, P14780, Q15744, Q16548, O15550, P05164, P12838, P08246, Q9C0K0, P24522 | SS18, ATM, MMP9, CEBPE, BCL2A1, UTX, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | |
| Gatifloxacin | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
| Gatifloxacin | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Gatifloxacin | hsa05231 | Choline metabolism in cancer | 2.00E-02 | 2 | Q9Y259, P49619 | CHKB, DGKG | More | |
| Gatifloxacin | hsa05321 | Inflammatory bowel disease | 2.29E-02 | 4 | P13765, Q14765, P23771, Q9HBE5 | HLA-DOB, STAT4, GATA3, IL21R | More | |
| Gatifloxacin | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Gatifloxacin | hsa05332 | Graft-versus-host disease | 7.89E-03 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | |
| Gatifloxacin | hsa05415 | Diabetic cardiomyopathy | 2.87E-02 | 4 | P05141, O15239, P13073, Q13557 | SLC25A5, NDUFA1, COX4I1, CAMK2D | More | |
